Holen Sie sich die Stockscreener-App
17.58
1.02%
0.1781
Handel nachbörslich:
17.58
0.0019
+0.01%
Schlusskurs vom Vortag:
$17.40
Offen:
$17.5147
24-Stunden-Volumen:
2,252
Relative Volume:
0.64
Marktkapitalisierung:
$424.83M
Einnahmen:
$1.70M
Nettoeinkommen (Verlust:
$-47.01M
KGV:
-10.34
EPS:
-1.7
Netto-Cashflow:
$-157.28M
1W Leistung:
+5.64%
1M Leistung:
+4.94%
6M Leistung:
-2.78%
1J Leistung:
+0.16%
1-Tages-Spanne:
$17.13
$17.58
1-Wochen-Bereich:
$16.65
$17.70
52-Wochen-Spanne:
$13.30
$20.00
Puretech Health Plc Adr Stock (PRTC) Company Profile
Firmenname
Puretech Health Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
17.58 | 420.53M | 1.70M | -47.01M | -157.28M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
Puretech Health Plc Adr Aktie (PRTC) Neueste Nachrichten
PRTC Stock Price and Chart — NASDAQ:PRTC - TradingView — Track All Markets
PureTech Health (NASDAQ:PRTC) Trading Up 5.7% – Here’s Why - Defense World
PureTech CEO to present at J.P. Morgan Healthcare Conference By Investing.com - Investing.com India
PureTech CEO to present at J.P. Morgan Healthcare Conference - Investing.com
QBE Insurance Group Limited – Sponsored ADR (OTCMKTS:QBIEY) Short Interest Update - Defense World
PureTech Health appoints Robert Lyne as permanent CEO - Investing.com
PureTech Health appoints Robert Lyne as permanent CEO By Investing.com - Investing.com India
PureTech Health (NASDAQ:PRTC) Trading Down 0.7% – Time to Sell? - Defense World
PureTech Health (NASDAQ:PRTC) Trading Down 0.7%Time to Sell? - MarketBeat
FDA supports PureTech’s deupirfenidone for IPF to advance to phase 3 - Investing.com
PureTech Health (NASDAQ:PRTC) Trading 0.4% HigherStill a Buy? - MarketBeat
PureTech Health (NASDAQ:PRTC) Stock Price Up 3.1%Time to Buy? - MarketBeat
PureTech Health PLC Sponsored ADR $PRTC Shares Sold by Birch Hill Investment Advisors LLC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 100.0% in September - MarketBeat
Free cash flow per share of PureTech Health PLC Sponsored ADR – NASDAQ:PRTC - TradingView
PureTech Health (NASDAQ:PRTC) Trading Up 3.6%Here's What Happened - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Significant Growth in Short Interest - MarketBeat
PureTech Health (LON:PRTC) Shares Up 14.2% – Should You Buy? - Defense World
PureTech Health Sees Strong Market Presence in FTSE All Share - Kalkine Media
Parallel Advisors LLC Acquires 1,718 Shares of GSK PLC Sponsored ADR $GSK - Defense World
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Large Growth in Short Interest - MarketBeat
BioHarvest Sciences (BHST) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech Health (NASDAQ:PRTC) Shares Up 4.7%Time to Buy? - MarketBeat
PureTech Health Cash Runway Extended - The Motley Fool
International Flavors & Fragrances (NYSE:IFF) & DAQO New Energy (NYSE:DQ) Critical Comparison - Defense World
Conference Calls and Individual Investors - MarketBeat
Deupirfenidone: A Potential New Standard of Care - Placera.se
PureTech launches new entity to advance IPF treatment deupirfenidone - Investing.com
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health to report half-yearly results on August 28 By Investing.com - Investing.com South Africa
PureTech Health (NASDAQ:PRTC) Trading Up 1.4% – Still a Buy? - Defense World
PureTech Health (NASDAQ:PRTC) Shares Down 7.3% – Here’s What Happened - Defense World
PureTech’s Seaport doses first patient in phase 2b depression study By Investing.com - Investing.com South Africa
PureTech Health names Robert Lyne as interim CEO as Chowrira departs - Investing.com
PureTech Health names Robert Lyne as interim CEO as Chowrira departs By Investing.com - Investing.com India
Big Oil's Q2 Outlook: Downstream Gains and Upstream Pains - The Globe and Mail
PureTech Health announces board leadership transition By Investing.com - Investing.com South Africa
PureTech Health announces board leadership transition - Investing.com
PureTech Health announces board chair Raju Kucherlapati steps down - Investing.com
PureTech Health issues shares to executives following RSU vesting - Investing.com
PureTech Health announces RSU vesting and share transactions by PDMR - Investing.com
Citius Oncology (CTOR) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech set for Jefferies Global Healthcare Conference chat - Investing.com
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
PureTech Health enlists Peel Hunt as joint broker - Investing.com
Invesco Ltd: Form 8.3PureTech Health PLC; Opening Position disclosure - The Manila Times
Nordic Capital XI ends pursuit of PureTech acquisition - Investing.com
PureTech Health (LSE: PRTC) Presents Promising Phase 1b Data for LYT-200 in AML and MDS at ASH 2024 - Kalkine Media
India Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Argentina Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Finanzdaten der Puretech Health Plc Adr-Aktie (PRTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):